Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer
Yu Mei, Min Shi, Zhenglun Zhu, Hong Yuan, Chao Yan, Chen Li, Tienan Feng, Min Yan, Jun Zhang, Zhenggang Zhu, Yu Mei, Min Shi, Zhenglun Zhu, Hong Yuan, Chao Yan, Chen Li, Tienan Feng, Min Yan, Jun Zhang, Zhenggang Zhu
Abstract
The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive. Peritoneal recurrence is the common and severe relapse pattern. Nanoparticle albumin-bound paclitaxel (Nab-PTX) is safer and more effective than PTX in the peritoneal metastasis. Clinical trial has demonstrated the safety and efficacy of sintilimab in GC. A combination of Nab-PTX, S-1 and sintilimab could be a promising triplet regimen as adjuvant therapy for GC. The aim of this article is to describe the design of this prospective Dragon-VII trial, conducted to evaluate the safety and efficacy of the combination of Nab-PTX, S-1 and sintilimab. Clinical trial registration: NCT04781413.
Keywords: Adjuvant therapy; S-1; Sintilimab; gastric cancer; nanoparticle albumin-bound paclitaxel.
Source: PubMed